CY1124454T1 - Συνθεσεις ινσουλινης ταχειας-δρασης - Google Patents

Συνθεσεις ινσουλινης ταχειας-δρασης

Info

Publication number
CY1124454T1
CY1124454T1 CY20211100747T CY211100747T CY1124454T1 CY 1124454 T1 CY1124454 T1 CY 1124454T1 CY 20211100747 T CY20211100747 T CY 20211100747T CY 211100747 T CY211100747 T CY 211100747T CY 1124454 T1 CY1124454 T1 CY 1124454T1
Authority
CY
Cyprus
Prior art keywords
rapid
acting insulin
insulin compositions
insulin analog
insulin
Prior art date
Application number
CY20211100747T
Other languages
English (en)
Inventor
Michael Edward CHRISTE
Thomas Andrew HARDY
Original Assignee
Eli Lilly And Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53189204&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1124454(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Co. filed Critical Eli Lilly And Co.
Publication of CY1124454T1 publication Critical patent/CY1124454T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Η εφεύρεση είναι μία σύνθεση ανθρώπινης ινσουλίνης ή ανάλογου ινσουλίνης που περιλαμβάνει τρεπροστινίλη και που έχει ταχύτερη φαρμακοκινητική δράση από ότι εμπορικά σκευάσματα υπαρχόντων προϊόντων αναλόγων ινσουλίνης.
CY20211100747T 2014-05-08 2021-08-20 Συνθεσεις ινσουλινης ταχειας-δρασης CY1124454T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461990402P 2014-05-08 2014-05-08
PCT/US2015/029010 WO2015171484A1 (en) 2014-05-08 2015-05-04 Rapid-acting insulin compositions
EP15723388.3A EP3140008B1 (en) 2014-05-08 2015-05-04 Rapid-acting insulin compositions

Publications (1)

Publication Number Publication Date
CY1124454T1 true CY1124454T1 (el) 2022-07-22

Family

ID=53189204

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20191100581T CY1121669T1 (el) 2014-05-08 2019-05-31 Συνθεσεις ινσουλινης ταχειας-δρασης
CY20211100747T CY1124454T1 (el) 2014-05-08 2021-08-20 Συνθεσεις ινσουλινης ταχειας-δρασης

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20191100581T CY1121669T1 (el) 2014-05-08 2019-05-31 Συνθεσεις ινσουλινης ταχειας-δρασης

Country Status (35)

Country Link
US (2) US9439952B2 (el)
EP (3) EP3140008B1 (el)
JP (1) JP6050902B2 (el)
KR (1) KR101858890B1 (el)
CN (1) CN106456717B (el)
AP (1) AP2016009525A0 (el)
AR (1) AR100155A1 (el)
AU (1) AU2015256355B2 (el)
BR (1) BR112016024357B1 (el)
CA (1) CA2945188C (el)
CL (1) CL2016002772A1 (el)
CY (2) CY1121669T1 (el)
DK (2) DK3140008T3 (el)
EA (1) EA031134B1 (el)
ES (2) ES2733639T3 (el)
HR (2) HRP20190777T1 (el)
HU (2) HUE055742T2 (el)
IL (1) IL248350B (el)
JO (1) JO3624B1 (el)
LT (2) LT3536380T (el)
MA (1) MA39441A1 (el)
ME (1) ME03384B (el)
MX (1) MX367521B (el)
NZ (1) NZ724919A (el)
PE (1) PE20161408A1 (el)
PH (1) PH12016502195B1 (el)
PL (2) PL3536380T3 (el)
PT (2) PT3536380T (el)
RS (2) RS58726B1 (el)
SG (1) SG11201608424WA (el)
SI (2) SI3536380T1 (el)
TN (1) TN2016000443A1 (el)
TR (1) TR201906843T4 (el)
TW (1) TWI685348B (el)
WO (1) WO2015171484A1 (el)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
EP3332810B1 (fr) 2012-11-13 2021-01-13 Adocia Formulation à action rapide d'insuline comprenant un composé anionique substitué
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
EP3712142B1 (en) 2013-01-11 2022-07-06 Corsair Pharma, Inc. Prodrugs of treprostinil
EP3328388B1 (en) * 2015-07-28 2023-12-27 Eli Lilly and Company A pharmaceutical preparation for improving absorption and postprandial hypoglycemic action of insulin
JO3749B1 (ar) * 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
EP4079291A1 (en) * 2016-01-29 2022-10-26 MannKind Corporation Dry powder inhaler
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
CA3038276A1 (en) 2016-09-26 2018-03-29 United Therapeutics Corporation Treprostinil prodrugs
WO2018060735A1 (en) 2016-09-29 2018-04-05 Arecor Limited Novel formulations
DK3554534T3 (da) 2016-12-16 2021-08-23 Novo Nordisk As Farmaceutisk sammensætning omfattende insulin
GB201707187D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707189D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707188D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
JOP20190277B1 (ar) 2017-06-01 2023-09-17 Lilly Co Eli تركيبات إنسولين سريعة المفعول
US20210093775A1 (en) * 2018-04-04 2021-04-01 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
CA3094308A1 (en) 2018-04-04 2019-10-10 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
CN111989088A (zh) 2018-04-04 2020-11-24 艾瑞克有限公司 用于递送胰岛素化合物的医用输注泵系统
FR3083985A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
WO2019243627A1 (fr) 2018-06-23 2019-12-26 Adocia Dispositif pour injecter une solution d'insuline(s)
CN112739679B (zh) 2018-09-18 2024-03-12 伊莱利利公司 曲前列环素的特丁胺盐
US10799564B1 (en) 2019-05-06 2020-10-13 Baxter International Inc. Insulin premix formulation and product, methods of preparing same, and methods of using same
WO2021041320A1 (en) 2019-08-23 2021-03-04 United Therapeutics Corporation Treprostinil prodrugs
GB202004814D0 (en) 2020-04-01 2020-05-13 Arecor Ltd Novel formulations
CN115916212A (zh) 2020-04-17 2023-04-04 联合治疗公司 曲前列尼尔用于治疗间质性肺病
EP4161909A1 (en) 2020-06-09 2023-04-12 United Therapeutics Corporation Fumaryl diketopiperidine prodrugs of treprostinil
WO2022002008A1 (zh) * 2020-06-30 2022-01-06 江苏恒瑞医药股份有限公司 速效胰岛素组合物及其医药用途
KR20230134480A (ko) 2020-12-14 2023-09-21 유나이티드 쎄러퓨틱스 코포레이션 트레프로스티닐 프로드러그로 질환을 치료하는 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2740953A1 (de) 1977-09-12 1979-03-22 Thera Ges Fuer Patente Verwendung von prostaglandinen zur senkung des blutzuckerspiegels
JPH10251146A (ja) 1997-03-11 1998-09-22 Toray Ind Inc 糖尿病性神経障害の治療方法
EP1432430A4 (en) * 2001-08-28 2006-05-10 Lilly Co Eli PREMIXTURES OF GLP-1 AND BASALINSULIN
AU2003236201A1 (en) 2002-05-07 2003-11-11 Novo Nordisk A/S Soluble formulations comprising monomeric insulin and acylated insulin
ATE462427T1 (de) * 2004-04-12 2010-04-15 United Therapeutics Corp Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
US20090054473A1 (en) * 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapy for complications of diabetes
DK2626093T3 (en) 2008-08-28 2014-02-24 Hoffmann La Roche DEVICE FOR INCREASING HYPODERMIC insulin absorption
JP2012503668A (ja) * 2008-09-25 2012-02-09 アラダイム コーポレーション 肺深部へのトレプロスチニルの肺送達
JP5669834B2 (ja) * 2009-06-26 2015-02-18 ノボ・ノルデイスク・エー／エス インスリン、ニコチンアミド及びアミノ酸を含む製剤
TWI513462B (zh) * 2009-11-13 2015-12-21 Toray Industries 糖尿病之治療或預防藥
WO2012080362A1 (en) 2010-12-14 2012-06-21 Novo Nordisk A/S Preparation comprising insulin, nicotinamide and an amino acid
CN103857413A (zh) * 2011-08-12 2014-06-11 阿森迪斯药物股份有限公司 载体连接的曲罗尼尔前药
US9381247B2 (en) * 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
US20150065423A1 (en) 2013-08-30 2015-03-05 Perosphere, Inc. Rapid acting injectable formulations
WO2015120457A1 (en) 2014-02-10 2015-08-13 Biodel Inc. Stabilized ultra-rapid-acting insulin formulations

Also Published As

Publication number Publication date
TW201625291A (zh) 2016-07-16
EA031134B1 (ru) 2018-11-30
SI3140008T1 (sl) 2019-06-28
KR101858890B1 (ko) 2018-05-16
EP3140008B1 (en) 2019-04-17
AP2016009525A0 (en) 2016-10-31
CA2945188C (en) 2018-12-11
DK3140008T3 (da) 2019-06-24
CA2945188A1 (en) 2015-11-12
PH12016502195A1 (en) 2017-02-06
CL2016002772A1 (es) 2017-06-09
KR20160133567A (ko) 2016-11-22
IL248350A0 (en) 2016-11-30
EP3536380B1 (en) 2021-07-07
RS62291B1 (sr) 2021-09-30
PT3536380T (pt) 2021-09-02
EA201691911A1 (ru) 2017-02-28
ME03384B (me) 2020-01-20
BR112016024357B1 (pt) 2022-08-23
US20160367640A1 (en) 2016-12-22
PH12016502195B1 (en) 2017-02-06
PL3536380T3 (pl) 2021-12-27
HRP20190777T1 (hr) 2019-08-23
AU2015256355A1 (en) 2016-10-27
JP2016523807A (ja) 2016-08-12
US10172922B2 (en) 2019-01-08
TN2016000443A1 (en) 2018-04-04
PE20161408A1 (es) 2016-12-28
PL3140008T3 (pl) 2019-09-30
WO2015171484A1 (en) 2015-11-12
US9439952B2 (en) 2016-09-13
LT3140008T (lt) 2019-05-27
RS58726B1 (sr) 2019-06-28
MX367521B (es) 2019-08-26
BR112016024357A2 (pt) 2017-10-10
SG11201608424WA (en) 2016-11-29
TWI685348B (zh) 2020-02-21
CN106456717B (zh) 2020-01-17
JO3624B1 (ar) 2020-08-27
NZ724919A (en) 2018-01-26
AR100155A1 (es) 2016-09-14
IL248350B (en) 2020-03-31
ES2733639T3 (es) 2019-12-02
HRP20211415T1 (hr) 2021-12-10
EP3943155A1 (en) 2022-01-26
TR201906843T4 (tr) 2019-05-21
MA39441A1 (fr) 2017-06-30
LT3536380T (lt) 2021-08-10
CY1121669T1 (el) 2020-07-31
MX2016014643A (es) 2017-03-06
EP3536380B8 (en) 2021-09-22
EP3140008A1 (en) 2017-03-15
CN106456717A (zh) 2017-02-22
HUE055742T2 (hu) 2021-12-28
AU2015256355B2 (en) 2017-09-14
EP3536380A1 (en) 2019-09-11
ES2891983T3 (es) 2022-02-01
HUE044370T2 (hu) 2019-10-28
DK3536380T3 (da) 2021-08-02
SI3536380T1 (sl) 2021-09-30
JP6050902B2 (ja) 2016-12-21
US20160129087A1 (en) 2016-05-12
PT3140008T (pt) 2019-06-25

Similar Documents

Publication Publication Date Title
CY1124454T1 (el) Συνθεσεις ινσουλινης ταχειας-δρασης
MD3340966T2 (ro) Compoziții de insulină cu acțiune rapidă
BR112016022062A2 (pt) Combinação, composição farmacêutica, uso de uma combinação ou de uma composição farmacêutica, e, produto farmacêutico
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
GB201613397D0 (en) Cosmetic composition comprising silicone materials
GB201701915D0 (en) Fabric care composition comprising silicone materials
DK3821905T3 (da) Insulin indeholdende farmaceutiske sammensætninger
IL280690A (en) Pharmaceutical preparations that include DGLA and their use
MX2017000862A (es) Formulacion de factor viii.
MX2017005812A (es) Composiciones de limpieza.
BR112016026470A2 (pt) Composto modulador de hsp70, composição farmacêutica que o compreende e uso do referido composto
FI20165153A (fi) Lyofilisoitu farmaseuttinen formulaatio ja sen käyttö
MA51009A (fr) Composition de soins buccaux
DK3099314T3 (da) Tolerogene sammensætninger og anvendelser deraf
GB201401706D0 (en) Nanoparticle-insulin and insulin analogue compositions
PL3492143T3 (pl) Kompozycja o niskiej lepkości do pielęgnacji zębów
CO2019013251A2 (es) Composiciones de insulina de rápida acción
MA51010A (fr) Compositions de soins buccodentaires
TH1601002041A (th) องค์ประกอบของวัสดุทางแสงและวัสดุทางแสงซึ่งใช้สิ่งนั้น
TH1601003209A (th) องค์ประกอบเครื่องสำอางที่เป็นผง
TH1501006461A (th) อนุพันธ์ของโดลาสแททิน 10 และออริสแททิน (Derivatives of dolastatin 10 and auristatins)